137 citations
,
December 2006 in “Arthritis Research & Therapy” Mycophenolate mofetil is safer and more effective than cyclophosphamide for treating lupus nephritis.
7 citations
,
January 2025 in “Journal of Experimental & Clinical Cancer Research” PRMT5 inhibitors effectively fight adenoid cystic carcinoma in salivary glands.
23 citations
,
December 2013 in “Molecular cancer therapeutics” Breast cancer treatments work better with AR activation, improving results and reducing side effects.
January 2025 in “Plastic Surgery and Reconstructive Medicine” Plasmatherapy improves immune status in vitiligo patients, especially those with segmental vitiligo.
November 2025 in “ACS Nano” The microreactor effectively fights antibiotic-resistant infections and promotes tissue healing.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
9 citations
,
March 2022 in “Journal of Chemical Information and Modeling” New inhibitors may reduce gut toxicity from cancer drugs.
1 citations
,
January 2007 in “The Kitakanto Medical Journal” Effective treatment for UFT overdose includes antibiotics and G-CSF, with bone marrow biopsy and transfusion as backup options.
136 citations
,
April 2013 in “Clinical Cancer Research” The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
January 2024 in “Pediatric rheumatology online journal” Early genetic testing and JAK inhibitors can help treat systemic inflammation in SAVI patients.
17 citations
,
January 1993 in “Journal of Gastroenterology and Hepatology” Interferon α‐2b can temporarily reduce hepatitis C virus and normalize liver enzyme levels.
30 citations
,
December 2019 in “PLoS ONE” The new delivery system improved raloxifene's skin absorption and effectiveness against cancer cells.
9 citations
,
November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
October 2021 in “Journal of Investigative Dermatology” COVID-19 infection rates were low in patients with immune diseases, regardless of their treatment type.
72 citations
,
November 2015 in “Multiple Sclerosis and Related Disorders” Teriflunomide is safe and tolerable for treating relapsing-remitting multiple sclerosis, with manageable side effects.
7 citations
,
December 2022 in “Skin Appendage Disorders” Certolizumab effectively treats psoriasis and psoriatic arthritis with fewer side effects than adalimumab.
18 citations
,
October 2020 in “Radiation Research” Some drugs may help treat both COVID-19 and radiation injury.
2 citations
,
September 2018 in “JAAD case reports” A rare type of skin cancer with mucosal involvement was partially treated but eventually relapsed.
January 2025 in “Nanoscale Advances” The nanocomposite effectively targets lung cancer cells without harming normal cells.
4 citations
,
July 2021 in “Cancer Research and Treatment” Temozolomide improves survival in grade III glioma patients without harming quality of life.
March 2025 in “Pediatric Rheumatology” Cyclophosphamide is preferred for severe cases in pediatric rheumatology and nephrology despite its side effects.
September 2013 in “Oncology Times” Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.
May 2025 in “The Journal of Rheumatology” Anifrolumab may help improve symptoms in patients with overlapping autoimmune diseases.
September 2023 in “SKIN The Journal of Cutaneous Medicine” Talquetamab may cause hair loss and skin issues.
9 citations
,
March 2024 in “Journal of Biomaterials Applications” Rizatriptan benzoate-loaded dissolving microneedles are effective and convenient for treating acute migraines.
85 citations
,
January 1996 in “International Journal of Cancer” AS101 reduces hair loss from chemotherapy.
2 citations
,
July 2025 in “RMD Open” IL-1 blockade is effective for treating SURF, and personalized treatment is needed.
September 2022 in “Journal of the American Academy of Dermatology” The registry showed that tofacitinib is promising for treating hair loss in children with alopecia areata, but more research is needed.
47 citations
,
December 2019 in “Frontiers in immunology” A new mutation in the STING protein causes a range of symptoms and its severity may be affected by other genetic variations; treatment with a specific inhibitor showed improvement in one patient.
November 2025 in “The Journal of Immunology” A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.